NEWS: Blueberries Medical Signs Framework Agreement with YVY Life Sciences of Uruguay.
Toronto, Ontario (March 26, 2021) – Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) the Canadian parent of Blueberries S.A.S., the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"),today announced that it has signed a Framework Agreement with Mechelen S.A., a subsidiary of YVY Life Sciences (“YVY”) for mutual development of strains and genetics in Colombia and potentially exporting dry cannabis flower of mutual strains from Uruguay.This is Blueberries’ first agreement in Uruguay and the next step in Blueberries’ international growth strategy under way. In December 2013, Uruguay, became the first country in the world to legalize recreational cannabis, starting a ripple effect throughout the world and particularly in Latin America, which continues to this day. With this agreement, Blueberries will expand its reach to a new jurisdiction, and through the Mercosur Regional Free Trade Bloc, will gain access to Brazil. Latin America, which includes Colombia, Argentina, Peru and Uruguay, is a highly populous potential market, with countries that have recent or pending legislation permitting access to cannabis and CBD oils for medicinal use. YVY is dedicated to the production of dried flowers of medicinal cannabis with their focus on sustainable and high-quality cannabis and hemp cultivation, harvesting their first sustainable crops in April 2020. “We are incredibly pleased with the concept of co-developing new cannabis genetics in collaboration with YVY, and with the opportunity to replicate their unique cultivation model that will bring multiple benefits to our operations in Colombia.” said Jose Forero, Blueberries President of Latin American Operations, “Likewise, we are excited with the opportunity to register our top genetics in other countries. Uruguay is the perfect jurisdiction to start our expansion into new geographies and potentially export dry flower, something that is not yet allowed in Colombia.” The Framework Agreement, dated March 24, 2021, has an initial term of five years, with customary renewal clauses and no consideration paid by neither party. It is intended as the first step in the relationship with specific accessory agreements to follow in the coming months. Under the Framework Agreement, Blueberries and YVY will structure collaborative plans, initially starting with mutual development of strains and genetics in Colombia, and consequently registration of those cultivars both in Colombia and Uruguay. This will provide a fast-track opportunity to register Blueberries’ proprietary genetics in Uruguay, thus allowing the partners to cultivate and export dry flower of Blueberries’ strains from Uruguay. “We are thrilled with this strategic alliance with Blueberries as we venture beyond Uruguay. Our goal is to work closely with Blueberries to replicate YVY’s unique cultivation model with small producers in Colombia, producing high-quality and natural products while generating scalable social and environmental impact,” said Andrea Krell, Chief Executive Officer of YVY. “Our vision is to use the Framework Agreement as the first step in a long-term strategic partnership which
will help us quickly take practical steps in developing collaborative projects both in Colombia and Uruguay.” About YVY Life Sciences YVY is a cannabis lifestyle brand comprising of natural and high-quality products, powered by an innovative and unique cultivation model. YVY operations are currently in Uruguay with expansion plans underway in Colombia and Argentina with potential distribution in Latin America and Europe. YVY’s focus and expertise is the cultivation of high-quality cannabis flower, biomass and seeds incorporating genetics R&D and strict quality control. YVY works with strategic partners to manufacture, formulate, and distribute YVY branded products targeting the wellness segment. For more information about the YVY visit www.yvylifesciences.com, or please contact: Andrea K Krell, Chief Executive Officer andrea@yvylifesciences.comTel: +598 92 151 456 About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. Additional information about the Company is available at www.blueberriesmed.com.
